Nexien BioPharma (NXEN) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 2, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the filing for Q3 FY2025, filed May 14, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NXEN SEC filings page.
This page shows Nexien BioPharma Inc (NXEN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings.
Financial Health Signals
We do not publish a peer-relative financial health score for Nexien BioPharma Inc, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
Nexien BioPharma Inc reported a net loss of $30K in Q3 2025. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Nexien BioPharma Inc earned $0.00 per diluted share (EPS) in Q3 2025. This represents a decrease of 100.0% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2025.
Not reported for Q3 2025.
Cash & Balance Sheet
Nexien BioPharma Inc held $8K in cash as of Q3 2025; no long-term debt figure is on record for that period.
Not reported for Q3 2025.
Not reported for Q3 2025.
Margins & Returns
None of these metrics is reported for Q3 2025.
Capital Allocation
Nexien BioPharma Inc reported no research and development spending in Q3 2025. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2025.
Not reported for Q3 2025.
NXEN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'25Filing | Q2'25Filing | Q1'25Filing | Q4'24Filing | Q3'24Filing | Q2'24Filing | Q1'24Filing | Q4'23Filing |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $0n/m | $0n/m | $0n/m | N/A | $0 | $0 | $0n/m | N/A |
| SG&A Expenses | $5K-46.6% | N/A | $3K-93.5% | N/A | $9K-84.7% | $8K-88.3% | $46K-21.3% | N/A |
| Net Income | -$30Kn/m | N/A | N/A | N/A | -$53Kn/m | N/A | -$75Kn/m | N/A |
| EPS (Basic) | $0.00-100.0% | $0.00n/m | $0.00n/m | $0.00n/m | $0.00n/m | $0.00n/m | $0.00 | -$0.01n/m |
| EPS (Diluted) | $0.00-100.0% | $0.00n/m | $0.00n/m | $0.00n/m | $0.00n/m | $0.00n/m | $0.00 | -$0.01 |
| Diluted Shares (Avg) | 71M+6.6% | 71M+8.7% | 70M+9.1% | N/A | 66M+6.0% | 65M+5.2% | 65M | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Operating Income, EBITDA, Interest Expense, Income Tax.
NXEN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'25Filing | Q2'25Filing | Q1'25Filing | Q4'24Filing | Q3'24Filing | Q2'24Filing | Q1'24Filing | Q4'23Filing |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $8K-41.9% | $1K-50.1% | $5K-77.5% | $4K-90.3% | $14K-75.5% | $3K-96.6% | $22K-79.0% | $43K-65.4% |
| Current Assets | $8K-41.9% | $1K-50.1% | $5K-77.5% | $4K-90.3% | $14K-75.5% | $3K-96.6% | $22K-79.0% | $43K-65.4% |
| Cash & Equivalents | $8K-17.7% | $1K-50.1% | $5K-72.6% | $4K-88.1% | $10K-81.4% | $3K-96.2% | $18K-82.1% | $35K-69.9% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $459K+35.1% | $424K+33.8% | $397K+26.8% | $365K+23.8% | $340K+17.7% | $317K+13.4% | $313K+17.8% | $295K+21.9% |
| Current Liabilities | $459K+35.1% | $424K+33.8% | $397K+26.8% | $365K+23.8% | $340K+17.7% | $317K+13.4% | $313K+17.8% | $295K+21.9% |
| Non-Current Liabilities | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Equity | -$451Kn/m | -$423Kn/m | -$392Kn/m | -$361Kn/m | -$325Kn/m | -$314Kn/m | -$291Kn/m | -$252Kn/m |
| Retained Earnings | -$11.6Mn/m | -$11.6Mn/m | -$11.6Mn/m | -$11.5Mn/m | -$11.4Mn/m | -$11.4Mn/m | -$11.4Mn/m | -$11.3Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
NXEN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
NXEN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, Liabilities-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$361K), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.01), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Where Nexien BioPharma Inc Ranks
Frequently Asked Questions
Nexien BioPharma Inc (NXEN) had $4K in total assets as of fiscal year 2024, including both current and long-term assets.
Nexien BioPharma Inc (NXEN) had a current ratio of 0.01 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
Nexien BioPharma Inc (NXEN) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $7K as of Nov 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Nexien BioPharma Inc (NXEN) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $7K as of Nov 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Nexien BioPharma Inc (NXEN) has negative shareholder equity of -$361K as of fiscal year 2024, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.